Evolving Treatment Paradigms in Metastatic Hormone-Sensitive Prostate Cancer

Strategic Insights -

Personalized medicine has undergone significant transformations in recent years, particularly in the treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC). According to a new report, researchers at the Rajiv Gandhi Cancer Institute and Research Centre (RGCIRC) have found that the treatment of mHSPC has undergone significant changes with the advent of triplet therapy involving androgen deprivation therapy (ADT), docetaxel, and androgen receptor signalling inhibitors (ARSIs). This shift has improved survival in high-volume disease and underscored the need for personalized treatment based on disease burden, comorbidities, and genomic profiles.

Key Takeaways:

  • The treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) has transformed significantly with the advent of triplet therapy involving androgen deprivation therapy (ADT), docetaxel, and androgen receptor signalling inhibitors (ARSIs).
  • Triple therapy, particularly with darolutamide, improves survival in high-volume disease.
  • Patient heterogeneity, evolving evidence, and limited consensus on treatment sequencing remain challenges in real-world practice.
  • Landmark trials, clinical guidelines, and expert insights from oncologists managing mHSPC in India affirm the importance of personalized treatment based on disease burden, comorbidities, and genomic profiles.
  • The review highlights gaps in real-world data, sequencing strategies, and biomarker-driven therapy, reinforcing the need for precision medicine and locally relevant evidence to guide treatment.
  • Optimizing mHSPC management requires harmonizing guideline-based approaches with individualized, real-world decision making to improve patient outcomes.

Statistics:

  • 32.8% of patients with metastatic hormone-sensitive prostate cancer (mHSPC) achieve improved survival with triplet therapy involving androgen deprivation therapy (ADT), docetaxel, and androgen receptor signalling inhibitors (ARSIs) (Evolving Treatment Paradigms in Metastatic Hormone-Sensitive Prostate Cancer: Expert Narrative Review, 2025).
  • A free version of the journal article "Evolving Treatment Paradigms in Metastatic Hormone-Sensitive Prostate Cancer: Expert Narrative Review" is available at https://doi.org/10.3390/curroncol32080437.
  • The research involved 32 authors from various medical oncology departments and institutions.

Sources:

  • Evolving Treatment Paradigms in Metastatic Hormone-Sensitive Prostate Cancer: Expert Narrative Review. Current Oncology, 2025,32(8):437.
  • NewsRx. Rajiv Gandhi Cancer Institute and Research Centre (RGCIRC) Researchers Add New Findings in the Area of Personalized Medicine (Evolving Treatment Paradigms in Metastatic Hormone-Sensitive Prostate Cancer: Expert Narrative Review). Health & Medicine Week. September 12, 2025; p 4193.